David's coverage specializes in OTC medicines, dietary supplements and self-care medical devices. David is interested in regulatory gray areas such as the borderlines between medicines, supplements and medical devices, as well as botanical ingredients. David also regularly speaks to industry leaders and experts about the latest trends to deliver crucial market intelligence to HBW Insight readers, and co-hosts the Over the Counter podcast. In his spare time, David spends time in his allotment garden, reading/watching science fiction and worrying about climate change.
Latest from David Ridley
Research from UK retailer Holland & Barrett, the University of East Anglia and the University of Southampton points to need for Omega-3 supplementation for many consumers.
Only taking inflation into account, the European Commission’s new cost estimate of between €1.48bn to €1.8bn per year, when adjusted for inflation, results in a total very similar to the original €1.2bn estimate.
Self-care solutions such as OTC drugs and wearables can save over 725,000 lives a year, argues a new report published by Reckitt and health insurance firm BUPA.
HBW Insight extracts lessons from six ASA rulings related to ads for prostate dietary supplement and self-test products, all of which fell foul of the regulators AI-powered Active Ad Monitoring system.
“In the coming years, growth will depend on whether brands can combine trust, personalization, and proof of evidence into one coherent prevention experience,” argue Simon Kucher's Clemens Oberhammer and Christian Rebholz in this exclusive interview.
While no doubt welcome, yet another delay to the EU Deforestation Law and suggestion for another review next year could mean a “never-ending” regulatory exercise that creates uncertainty for manufacturers selling products containing or having been made using materials like palm oil, soya and wood.